Novartis Selects GSK’s Saynor As Next Sandoz CEO

GlaxoSmithKline’s established products head, Richard Saynor, will return to Sandoz later this year to lead the Novartis division.

Novartis
Novartis has handed the top job at Sandoz to GSK executive Richard Saynor • Source: Shutterstock

Novartis has chosen Richard Saynor, currently senior vice-president of Classic & Established Products, Commercial & Digital Platforms at GlaxoSmithKline, to lead its Sandoz generics and biosimilars division. He will take over from interim head Francesco Balestrieri “no later than 1 August 2019” and will report directly to Novartis CEO Vas Narasimhan as a member of the Swiss group’s executive committee.

Saynor previously spent around five years with Sandoz, initially leading its operations in around 65 markets as head of Asia,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Leadership

More from Generics Bulletin